Clinical Research Directory
Browse clinical research sites, groups, and studies.
7 clinical studies listed.
Filters:
Tundra lists 7 Epilepsy, Drug Resistant clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06436547
Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Subiculum as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis
Gender: All
Ages: 14 Years - 65 Years
Updated: 2025-11-19
1 state
NCT07128563
Piriform Cortex Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Piriform cortex as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis
Gender: All
Ages: 14 Years - 65 Years
Updated: 2025-08-19
NCT06248333
Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of subthalamic nucleus (STN) as adjunctive therapy for reducing the frequency of seizures in drug-resistant focal motor epilepsy.
Gender: All
Ages: 14 Years - 65 Years
Updated: 2025-07-15
1 state
NCT06719791
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)
The aim of this study is to evaluate the clinical efficacy of sirolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.
Gender: All
Ages: 18 Years - 60 Years
Updated: 2024-12-31
NCT06719804
Propranolol Adjuvant Treatment of Focal Refractory Epilepsy (PATFRE)
The aim of this study is to evaluate the clinical efficacy of propranolol as an adjunctive treatment for refractory epilepsy. The significance of this research lies in exploring whether propranolol, as an inhibitor of the CAMP-PKA-MEK/ERK pathway, can provide anticonvulsant effects for a wider range of refractory epilepsy patients. The study holds the potential to offer a novel adjunctive anticonvulsant treatment strategy targeting the CAMP-PKA-MEK/ERK pathway, specifically administered for seizure events, and applicable to various forms of refractory epilepsy.
Gender: All
Ages: 18 Years - 60 Years
Updated: 2024-12-10
NCT06663124
Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy
Evaluation of the Efficacy and Safety of Deep Brain Stimulation of the Extreme Capsule (EC) for the Treatment of Drug-Resistant Epilepsy
Gender: All
Ages: 14 Years - 65 Years
Updated: 2024-10-29
1 state
NCT06364085
Enhancing Epilepsy Management With Precision Deep Brain Stimulation
The goal of this study is to evaluate the effectiveness of objective neural response feedback on deep brain stimulation (DBS) programming for drug-resistant epilepsy in a prospective observational cohort study.
Gender: All
Updated: 2024-04-15
1 state